Dasatinib price and availability

Dasatinib (Dasatinib) is a gray to yellow solid chemical and an anti-tumor drug. It is mainly used to treat adult patients with Philadelphia chromosome-positive (Ph+) CML in the chronic phase, accelerated phase and blast phase who are resistant or intolerant to imatinib mesylate.

For the chronic phase of chronic myelogenous leukemia, the recommended dose of dasatinib is 100 mg per day, which can be increased to 140 mg per day; for the advanced phase of chronic myelogenous or lymphocytic leukemia or Ph chromosome-positive acute lymphoblastic leukemia, the initial dose is 70 mg per day, which can be increased to 100 mg per day. Dasatinib may include bone marrow suppression, allergic reactions, fluid retention, abnormal bleeding, and liver function impairment.

In conclusion, dasatinib is an effective anti-tumor drug and provides a new treatment option for many leukemia patients. When using it, you should follow your doctor's advice, pay attention to monitoring side effects and adjust the treatment plan in a timely manner.

Today, dasatinib has entered the domestic market and has been included in the reimbursement scope of Class B medical insurance. There are two types of dasatinib on the market: original drugs and domestic generic drugs. Each box of original research dasatinib contains 60 tablets of 50mg, and the price after medical insurance reimbursement is about 5,000 yuan. The domestic generic version is available in 7 tablets of 50mg and sells for about 400 yuan. In addition, generic dasatinib is also available on the market in India and Bangladesh. The price of 50mg*60 tablets ranges from 600 to 1,000 yuan. Compared with domestic products, these overseas versions are more cost-effective. If patients need more questions about dasatinib, please consult the Yaofenxiang medical consultant for more information.